Allen Ho, MD
Ophthalmology · Plymouth Meeting, PANPI 1922056712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $205,469 of the $225,237 with a category attached, or 91.2%. 25 manufacturers reported payments, led by Regeneron at 33.6% of the total. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $1265.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$76K
- Regeneron Healthcare Solutions, Inc.$30K
- Alcon Research LLC$26K
- Alcon$21K
- Eyepoint US, Inc.$16K
- Notal Vision, Inc.$10K
- plus $47K from 19 others
Across 74 payments — averaging $14,656 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$729K
- Novartis$269K
- Aerie Pharmaceuticals, Inc.$34K
- AbbVie$21K
- Regeneron$17K
- Alcon Research LLC$10K
- plus $5K from 1 others
What the payments were for
- Consulting fees$205,46991%
- Speaking & faculty fees$6,2973%
- Travel & lodging$6,9973%
- Food & beverage$6,3313%
- Gifts$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 41 | $75,734 |
| Regeneron Healthcare Solutions, Inc. | 8 | $29,562 |
| Alcon Research LLC | 17 | $25,596 |
| Alcon | 17 | $21,121 |
| Eyepoint US, Inc. | 16 | $15,658 |
| Notal Vision, Inc. | 4 | $10,172 |
| AbbVie(2 entities) | 11 | $9,095 |
| Genentech USA, Inc. | 14 | $8,402 |
| Janssen Research & Development, LLC | 3 | $6,610 |
| Neurotech Pharmaceuticals, Inc. | 4 | $5,876 |
| Apellis Pharmaceuticals, Inc. | 4 | $4,174 |
| Ocular Therapeutix, Inc. | 15 | $3,539 |
| Aerie Pharmaceuticals, Inc. | 5 | $3,320 |
| Genentech, Inc. | 4 | $3,178 |
| Dompe US, Inc. | 1 | $1,250 |
| Beaver-visitec International, Inc. | 2 | $1,197 |
| Abbott | 1 | $148 |
| Novartis | 1 | $122 |
| Alimera Sciences, Inc. | 3 | $113 |
| Biogen | 1 | $112 |
| Carl Zeiss Meditec, Inc. | 2 | $96 |
| Bausch & Lomb Americas Inc. | 1 | $68 |
| Astellas Pharma US Inc | 1 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Carl Zeiss Meditec USA, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$86,556
- EYP-1901$15,065
- ForeseeHome$10,125
- Lucentis$7,721
- ARGOS$6,300
- ENCELTO$5,643
- OZURDEX$3,100
- Rocklatan$3,000
- DEXTENZA$1,275
- EYLEA HD$1,105
- Constellation$1,050
- Proclaim IPG$148
- VABYSMO$123
- BUPARLISIB$122
- Syfovre$116
- NGENUITY$113
- BYOOVIZ$112
How this compares
$225,237 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 199 | $11,021 |
| ProlensaBromfenac Sodium | 17 | $5,966 |
| Ketorolac Tromethamine | 210 | $4,826 |
| Brimonidine Tartrate | 19 | $2,123 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 50 | $920 |
| Latanoprost | 43 | $562 |
| Atropine Sulfate | 13 | $497 |
| ErythromycinErythromycin Base | 34 | $374 |
| Dorzolamide Hcl | 14 | $302 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 27 | $229 |
| Timolol Maleate | 22 | $211 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.